The Sagility IPO is set to launch on November 5, 2024, with plans to raise ₹2,107 crore through a complete offer-for-sale. The Sagility IPO price is fixed at ₹30 per share, requiring a minimum investment of ₹15,000 for retail investors. With 75% of the IPO reserved for institutional buyers, Sagility offers a unique chance within India’s healthcare sector. The company’s 12% revenue growth and 59% increase in profits for FY2024 make it a compelling investment prospect. For those looking to develop their analysis skills for opportunities like this, GRM IIT provides top-tier investment education through YouTube and in-depth courses on our website.
Sagility IPO Details and Key Information
Understanding the Sagility IPO details is crucial for making an informed decision. Here’s a breakdown of the essential Sagility IPO information:
Key Sagility IPO Dates
- IPO Open Date: November 5, 2024
- IPO Close Date: November 7, 2024
- Sagility IPO Price Band: ₹30 per share
Sagility IPO Issue Size
- Total Issue Size: ₹2,107 crore (100% offer-for-sale)
- Retail Investor Quota: 10%
- Institutional Investor Quota: 75%
- Non-Institutional Investor Quota: 15%
These Sagility IPO details showcase the IPO’s scope, particularly its focus on institutional investment.
Financial Performance and Market Position
An in-depth Sagility IPO review of its financial performance reveals impressive growth figures:
Revenue Growth
- Increased from ₹4,236.06 crore in FY2023 to ₹4,781.5 crore in FY2024, reflecting approximately 13% year-on-year growth.
Profit After Tax (PAT)
- Rose from ₹143.57 crore in FY2023 to ₹228.27 crore in FY2024, a substantial 59% increase.
These Sagility IPO details indicate a solid foundation with strong financials, positioning Sagility competitively despite global competition in the healthcare sector.
Pros and Cons of Investing in the Sagility IPO
When determining whether the Sagility IPO is good or bad, it’s important to weigh the pros and cons:
Sagility IPO Review – Pros
- Strong Revenue Growth: Consistent increase, with 12% growth year-over-year.
- Unique Market Position: With no direct Indian competitors in healthcare services, the Sagility IPO offers a rare investment opportunity.
- Positive Sagility IPO GMP Review: Investors are closely watching the Sagility IPO GMP (Grey Market Premium) as an early indicator of interest.
Sagility IPO Review – Cons
- Market Volatility: Economic conditions may impact IPO performance.
- Global Competition: Though Sagility has a strong financial foundation, major competitors like Accenture and Cognizant could challenge its growth trajectory.
Sagility IPO GMP Review and Valuation Insights
The Sagility IPO GMP review provides insight into investor sentiment prior to listing. While the Sagility IPO GMP hasn’t been disclosed yet, monitoring this indicator can help investors gauge interest as the listing date approaches.
Conclusion: Is the Sagility IPO a Good Investment?
This Sagility IPO review shows that the company’s strong revenue and profit growth, along with its unique position in India’s healthcare market, make it a promising opportunity. However, potential investors should consider the risks posed by market volatility and global competition. If you want to learn advanced analysis techniques to evaluate IPOs like Sagility, GRM IIT is here to guide you.
Create Your Demat Account with GRM Bulls
To invest in the Sagility IPO and other potential opportunities, GRM Bulls provides comprehensive financial services, including assistance with Demat accounts. Click the button below to create your Demat account today:
Create Your Demat Account with GRM Bulls
Learn to Analyze Like a Pro with GRM IIT
For those eager to master IPO analysis, GRM IIT offers unmatched training. Visit our YouTube channel for free educational content, or explore our paid courses on our website to enhance your analysis skills and make well-informed investment decisions.